- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05689710
The Effects of Inositol on Glucose Metabolism in Patients With Metabolic Syndrome at Risk of Cardiac Fibrosis
November 15, 2023 updated by: Lo.Li.Pharma s.r.l
The Action of Inositols and Alpha-lactalbumin on Glucose Metabolism, Arterial Stiffness and Vascular Damage in Patients With Metabolic Syndrome at Risk of Cardiac Fibrosis
The study aims to evaluate the effects of an oral supplementation based on inositols and alpha-lactalbumin on principals metabolic parameters in patients with metabolic syndrome at risk of cardiac fibrosis
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Davide Grassi, MD
- Phone Number: +393332123716
- Email: davide.grassi@cc.univaq.it
Study Locations
-
-
-
L'Aquila, Italy
- Recruiting
- UOC Medicina Interna e Nefrologia P.O. AQ
-
Contact:
- Davide Grassi, MD
- Phone Number: 333 2123716
- Email: davide.grassi@cc.univaq.it
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
At least 3 of the following inclusion criteria:
- triglycerides levels ≥ 150 mg/dL
- HDL ≤ 40 mg/dL
- Fasting glycemia > 100 mg/dL <126 mg/dl
- Systolic Pressure ≥ 130 mmHg or Diastolic pressure ≥ 85 mmHg
- Hip circumference > 102 cm in men or 88 cm in women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: No intervention
|
|
Experimental: Experimental
Dietary Supplement with inositols and alpha-lactalbumin
|
The administration of an oral formulation based on inositol and alpha-lactalbumin (two sachets/day for 180 days)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Body weight
Time Frame: Four time points: changes in body weight (kg) from the baseline to 30, 90, 180 days
|
Four time points: changes in body weight (kg) from the baseline to 30, 90, 180 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tryglicerides
Time Frame: Four time points: changes in blood levels of tryglycerides from the baseline to 30, 90, 180 days
|
Plasmatic levels of tryglicerides
|
Four time points: changes in blood levels of tryglycerides from the baseline to 30, 90, 180 days
|
Hypertension
Time Frame: Four time points: changes in values of systolic and diastolic blood pressure from the baseline to 30, 90, 180 days
|
sphygmomanometer
|
Four time points: changes in values of systolic and diastolic blood pressure from the baseline to 30, 90, 180 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Davide Grassi, MD, UOC Medicina Interna e Nefrologia P.O. AQ
- Principal Investigator: Claudio Ferri, MD, UOC Medicina Interna e Nefrologia P.O. AQ
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 23, 2022
Primary Completion (Estimated)
December 1, 2023
Study Completion (Estimated)
June 1, 2024
Study Registration Dates
First Submitted
December 23, 2022
First Submitted That Met QC Criteria
January 10, 2023
First Posted (Actual)
January 19, 2023
Study Record Updates
Last Update Posted (Estimated)
November 16, 2023
Last Update Submitted That Met QC Criteria
November 15, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CARDIO_INO22
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome
-
Universidad de los Andes, ChileCompleted
-
Taipei Medical University WanFang HospitalUnknownMetabolic Cardiovascular SyndromeTaiwan
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
Mayo ClinicCompleted
-
University of HohenheimGerman Federal Ministry of Education and ResearchCompleted
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
Charite University, Berlin, GermanyRecruitingMetabolic Syndrome, Protection AgainstGermany
-
Wageningen University and ResearchPhilips Healthcare; TNO; Friesland Campina; Albert Heijn; Menzis; Smart with food; Vi... and other collaboratorsCompletedMetabolic Syndrome, Protection AgainstNetherlands
-
Cairo UniversityCompletedMetabolic Syndrome in WomenEgypt
-
Andalas UniversityHasanuddin University; Universitas Sumatera UtaraCompletedMetabolic Syndrome, Protection AgainstIndonesia
Clinical Trials on Inositol and alpha-lactalbumin
-
Lo.Li.Pharma s.r.lCompletedDysbiosis | Microbiota | Alpha-lactalbuminItaly
-
Lo.Li.Pharma s.r.lCompleted
-
AGUNCO Obstetrics and Gynecology CentreHospital Juarez de MexicoCompletedPolycystic Ovary SyndromeItaly, Mexico
-
Lo.Li.Pharma s.r.lCompleted
-
Waldkrankenhaus Protestant Hospital, SpandauHumana Inc.Completed
-
Lo.Li.Pharma s.r.lWithdrawnPCOS | Myo-inositol-resistance
-
George T. BuddUnited States Department of Defense; Anixa Biosciences, Inc.RecruitingResidual Disease | TNBC - Triple-Negative Breast Cancer | Pathologic Stage IIA-IIIC Triple-Negative Breast CancerUnited States
-
McMaster UniversityCompleted
-
NICHD Neonatal Research NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedRetinopathy of Prematurity | Bronchopulmonary Dysplasia (BPD) | Infant, Small for Gestational Age | Infant, Premature | Infant, Low Birth Weight | Infant, NewbornUnited States
-
G. d'Annunzio UniversityUniversity of ChietiUnknown